The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.
Company highlights during the first half of 2017 include China approval for Novaprep for non-gynecological cancer testing, and a €3 million private financing round.
The firm's real-time PCR-based GeneStat system was developed leveraging IP licensed exclusively from the Translational Genomics Research Institute.
The test, which is currently for research use only, uses fluorescent multiplex PCR to co-amplify seven markers for analysis of the MSI-high phenotype.
Thermo Fisher developed the NGS-based multi-marker assay in collaboration with Novartis and Pfizer to match lung cancer patients with targeted drugs.
Despite lower than expected NGS instrument sales, Illumina expects continued growth in the oncology market as reimbursement increases.
The company's test kit can ID pathogenic organisms and provide a measure of antibiotic susceptibility directly from positive blood culture samples.
The company's test kit provides identification and antimicrobial susceptibility testing of pathogens for patients suspected of bacteremia or fungemia.
During a conference call to discuss the firm's fourth quarter and full year 2015 earnings, company officials discussed their plans for 2016.
The molecular diagnostic test detects Shiga toxin-producing E. coli and the serotype O157 directly from a patient specimen.
A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.
Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.
In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.
A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.